Aileron Therapeutics, INC S-1 registration statements
Registration statements, filed ahead of a public offering, with the business description and financials a first-time investor sees.
Rein Therapeutics, Inc. has filed a registration statement for a proposed public offering of 30,000,000 shares of common stock to fund clinical development and operations.
Rein Therapeutics entered into a $15 million standby equity purchase agreement with Yorkville to fund clinical development, while facing a U.S. FDA clinical hold on its lead LTI-03 trial.